The arithmetic of Healwell AI’s latest earnings report tells two starkly different stories, and shareholders are left to decide which one matters more. On paper, the Canadian healthcare AI firm swung to an IFRS net profit of 6.4 million Canadian dollars in the second quarter of 2026, a dramatic reversal from the 4.1 million CAD loss posted a year earlier. But peel back that headline figure, and the operating picture looks considerably less rosy — revenue came in at 32.96 million CAD, narrowly missing the FactSet consensus, while adjusted EBITDA was cut in half to 1.1 million CAD from 2.3 million CAD.
The gap between those numbers is largely explained by a single, non-operational factor: the company’s indirect stake in SpaceX. Between the end of March and the end of June, the book value of that position ballooned from 4.6 million CAD to roughly 23 million CAD — a fivefold jump driven entirely by the valuation dynamics of one of the world’s hottest private companies, not by anything happening inside Healwell’s own operations. Management has signaled its intention to monetize the stake once the post-IPO lock-up period expires, a move that would fortify the balance sheet but also underscores just how dependent the current earnings picture has become on an asset outside the company’s core business.
The Margin Squeeze Behind the Numbers
The operational strain is not hard to locate. Gross profit contracted 4 percent to 17.9 million CAD, with the gross margin easing from 56 to 54 percent. Management attributes the pressure to a structural shift within the data science and AI division, which has been gravitating toward lower-margin, project-based work for life sciences clients. Extended sales cycles among enterprise customers have compounded the problem, though the company points to an active pipeline spanning multiple regions — deals in the Middle East, Canada, and the United States are reportedly in implementation phases and expected to be recognized in the second half of the year.
The full first half still shows meaningful momentum: revenue climbed 60 percent to 66.2 million CAD, and operating cash flow swung positive to 4.5 million CAD — a 14.4 million CAD improvement year over year. That cash generation, modest as it is, gives management some breathing room as it pursues integration and growth initiatives.
Guidance Trimmed, Targets Held
The company has, however, walked back its ambitions for the AI and data science segment, now guiding toward the lower end of its previously communicated 30-to-50 percent growth range. That implies roughly 30 percent growth and annualized revenue of around 13 million CAD for the division. The health software segment, meanwhile, is expected to grow only in the high single digits. Management reaffirmed its target of roughly 10 percent adjusted EBITDA margin by year-end 2026 and claims “line of sight” to 10 percent cross-sell penetration across the Orion Health customer base.
Should investors sell immediately? Or is it worth buying Healwell AI?
Analysts have responded with a mix of maintained conviction and reduced price targets. Stifel’s Justin Keywood trimmed his target to 2.25 US dollars from 2.50 on August 10, while Ventum Financial’s Rob Goff cut his to 1.75 US dollars from 2.50 the same day — both keeping “Buy” ratings. Haywood Securities also lowered its target to 1.75 US dollars, and Alliance Global Partners set a target of 1.50 Canadian dollars. Ventum’s Goff attributed the widespread target cuts to a sector-wide compression of SaaS valuation multiples rather than company-specific deterioration.
A Stock Trading Between Two Narratives
The market’s ambivalence is visible in the share price, which has been oscillating between enthusiasm over the SpaceX valuation and disappointment over operational metrics. The stock closed at 0.4450 euros, up 11.81 percent over seven days, yet remains 57.58 percent below its 52-week high of 1.05 euros reached in mid-August 2025. It also trades 16.40 percent below its 200-day moving average, and the year-to-date performance stands at minus 16.04 percent. A technical rating service downgraded the shares to “Sell Candidate” on August 7, a data point that reinforces the broader uncertainty. The stock hit its 52-week low of 0.3644 euros on February 24.
Beyond the financials, the company has operational milestones worth tracking. Pilot results for its SMART Summary and SMART Search solutions have been accepted for presentation at the AMIA Symposium in Dallas this November, and another region is slated to go live in the third quarter. A partnership with WELL Health Technologies also continues to provide support — the partner raised its 2026 revenue guidance to between 1.58 and 1.65 billion CAD and is deepening integration of Healwell’s clinical AI across its Canadian clinic network under the “OneWELL” strategy.
The Verdict Ahead
The next meaningful checkpoint arrives on November 16, when third-quarter results are due. By then, investors will have a clearer read on whether the margin improvement is taking hold and whether the AI segment’s growth is stabilizing near the lower bound of guidance. The bull case rests on the improved cash flow, the potential balance sheet boost from a SpaceX monetization, and the WELL Health partnership’s momentum. The bear case is equally straightforward: an eroding margin profile, a revenue miss, trimmed guidance, and a profit figure that could evaporate as quickly as it appeared if the SpaceX valuation reverses.
For now, Healwell AI trades as two stories in one ticker — a healthcare AI company with genuine operational traction and a leveraged bet on private-market valuation cycles. Which narrative ultimately wins out will determine whether the recent bounce is the start of a sustained recovery or merely a pause in a longer decline.
Ad
Healwell AI Stock: Buy or Sell?! New Healwell AI Analysis from August 12 delivers the answer:
The latest Healwell AI figures speak for themselves: Urgent action needed for Healwell AI investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 12.
Healwell AI: Buy or sell? Read more here...
